

Divisions of Hematologic Malignancies and Neoplasia

Multiple Myeloma

The Multiple Myeloma program of Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) provides comprehensive, state-of-the-art care, including promising new therapies through clinical trials. In addition, the center conducts an active program of basic and clinical research aimed at improving the outcomes of patients.

Comprehensive Services • We provide a range of services for patients with multiple myeloma. These include:

- consultation and confirmation of diagnosis;
- development of a personalized treatment plan offering the latest therapies (combination chemotherapy, novel biologically-based therapies, radiation therapy);
- access to clinical trials involving novel therapies (Phase I/II/III studies);
- stem cell transplantation;
- access to supportive and complementary therapies; and
- collaboration with patient's local physician, including for follow-up care closer to home.

Clinical Team • The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics encompass a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for multiple myeloma and someday a cure. The team includes:

Physicians

Kenneth C. Anderson, MD
 Paul G. Richardson, MD
 Robert L. Schlossman, MD
 Nikhil C. Munshi, MD
 Irene Ghobrial, MD

Nurse Practitioners/Physician Assistants

Mary McKenney, NP, RN, BSN, MSN
 Kim Noonan, NP, RN, BSN, MSN
 Mary Beth Nelson, PA

Research and Program Nursing

Deborah Doss, RN, BSN
 Kathleen Colson, RN, BSN
 Muriel Gannon, RN, BSN
 Kathleen McCormick, RN
 Stacey Chuma, RN, BSN

Our team leads in the development of the National Comprehensive Cancer Network's standard clinical practice guidelines for multiple myeloma.

Research • Our researchers identify and validate novel targets in myeloma, so that new therapies aimed at these targets can be developed, leading to improved outcomes and a cure. The center's research in the laboratory and the clinic is focused on several areas, including:

- investigations of the genetic abnormalities of myeloma cells;
- studies of the complex signaling that enables myeloma cells to grow and resist both conventional chemotherapy and novel therapy;
- efforts to unleash the power of the immune system against myeloma; and
- explorations of the way in which myeloma cells interact with their environment in the bone marrow and outside of the marrow compartment.

The Multiple Myeloma program at Dana-Farber is a founding Institution of the Multiple Myeloma Research Consortium (MMRC), which brings together an extraordinary assembly of distinguished myeloma researchers and world-renowned academic institutions to speed translational and clinical developments in myeloma.

This is a leading center for bench to bedside development of new treatments. The table on the following page highlights selected protocols currently accruing patients.

Selected Protocols for the Treatment of Multiple Myeloma

ID Number	Phase	Study Name	Principal Investigator
06-064	I	A Phase I Clinical Trial of NPI-0052 in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma	Paul G. Richardson, MD 617-632-2104
06-405	I	A Phase I, Multicenter, Open-label, Dose-escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal IgG1 antibody) in Patients with Advanced Multiple Myeloma	Nikhil C. Munshi, MD 617-632-5607
07-152	I	An Open-label Phase I Study of the Safety of Perifosine in Combination with Lenalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma	Paul G. Richardson, MD 617-632-2104
07-237	I	A Phase I Sequential Cohort, Dose-escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients with Refractory or Relapsed Multiple Myeloma	Nikhil C. Munshi, MD 617-632-5607
07-254	I	A Phase I Safety Study of Enzastaurin Plus Bortezomib Therapy in the Treatment of Relapsed or Refractory Multiple Myeloma	Irene Ghobrial, MD 617-632-4198
07-271	I	A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid [®] , cc-5013), and Dexamethasone in Patients with Multiple Myeloma	Nikhil C. Munshi, MD 617-632-5607
06-365	I/II	Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (VELCADE [®]) in Relapsed and/or Relapsed/Refractory Multiple Myeloma	Irene Ghobrial, MD 617-632-4198
07-190	I/II	A Phase I/II Study of VELCADE [®] (Bortezomib), Dexamethasone, and Revlimid [®] (Lenalidomid) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid (VDCR) in Patients with Previously Untreated Multiple Myeloma*	Paul G. Richardson, MD 617-632-2104
05-301	II	Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (Revlimid [™] , CC-5013) in Plasma Cell Dyscrasias	Nikhil C. Munshi, MD 617-632-5607
06-096	II	An Open-label, Phase II Study of the Safety and Efficacy of Perifosine and Bortezomib with or without Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Bortezomib*	Paul G. Richardson, MD 617-632-2104
06-147	II	An Open-label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients with Relapsed or Refractory Multiple Myeloma*	Paul G. Richardson, MD 617-632-2104
07-027	II	A Phase II Study of Oral LBH589 in Adult Patients with Multiple Myeloma Who have Received at Least Two Prior Lines of Therapy and Whose Disease is Refractory to the Most Recent Line of Therapy*	Kenneth C. Anderson, MD 617-632-2144
05-110	III	A Phase III Randomized Double-blind Study of Maintenance Therapy with CC-5013 (NSC #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma (CALGB 100104)	Robert L. Schlossman, MD 617-632-3265

* Protocol also available at Massachusetts General Hospital Cancer Center